Borge G Nordestgaard
@BNordestgaard
Followers
2K
Following
80
Media
65
Statuses
154
Clinical Professor at University of Copenhagen. President of European Atherosclerosis Society. Cardiovascular disease, cholesterol, Lp(a), remnants, FH, TG, LDL
Copenhagen
Joined June 2023
Read this article in the Economist (the worlds best weekly newspaper) on cholesterol, lipoproteins (HDL, LDL, Lp(a), remnants, VLDL, chylomicrons) and cardiovascular disease: https://t.co/8n6xIKZXTP Simpe and straightforward explanation of it all
8
100
529
There’s more to cholesterol than simply “good” or “bad”: The Economist with excellent story on cholesterol in the different lipoproteins and cardiovascular disease: HDL, LDL, Lp(a), remnants, VLDL and chylomicrons. Interesting to be interviewed to help shape this article
4
22
94
Frida Emanuelsson and Marianne Benn present innovative new genetic data relevant for drug development in weight loss. Just online in Eur Heart J: https://t.co/hSfW4BBpzk Honored and humble to be asked to co-author this excellent paper: Thanks
1
7
31
Liv T Nordestgaard et al here show that genetic lowering of non-HDL cholesterol via HMGCR, NPC1L1, and CETP reduces the risk of dementia - just published in Alzheimer's & Dementia: https://t.co/ovluLKMox3 The totality of data to come to this conclusion is impressive:
2
8
20
👉Lipids Spotlight at #ESCCongress An outstanding session covering the hottest topics in dyslipidemia: 🔹 LDL-C lowering – updates from @LaleTokgozoglu 🔹 Triglycerides – clinical impact with @BNordestgaard 🔹 Lp(a): small molecule, big trouble – insights from Florian
4
31
113
ASCVD risk reductions are expected for remnant cholesterol lowering drugs - if intervention trials with novel remnant cholesterol lowering drugs show expected reductions in remnants in cardiovascular outcomes trials: https://t.co/pjYy78h5Vm Mie Balling in Atherosclerosis
3
16
56
Remnant cholesterol lowering is associated with part of the cardiovascular risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials. A hitherto largely unnoticed clinically import fact: https://t.co/82eOiYqYht AT Nordestgaard & BG Nordestgaard in Eur J Prevent Cardiol
4
26
101
Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a). Mechanism driving ASCVD likely differ for LDL, remnants and Lp(a). https://t.co/agYrn4OiSq Anders B Wulff & BG Nordestgaard in Eur Heart J
3
53
166
Florian Kronenberg, Magda Daccord, et al made this important & influential document fly: "The Brussels International Declaration on Lipoprotein(a) Testing and Management". Patients, politicians, clinicians & sceintists: MEASURE Lp(A) IN ALL! https://t.co/HPdytUWk7Q Open access
4
14
55
In impaired renal function, low-grade inflammation and high remnant cholesterol jointly conferred highest risk of myocardial infarction, ASCVD, & all-cause mortality. D. Elías-López in Atherosclerosis https://t.co/sZCR3rQLRY CRP & remnant-C increase with lower kidney function:
2
11
30
A full house at #NLASessions for the W. Virgil Brown Distinguished Achievement Lectureship & Award.👏 Congratulations to this year’s recipient, @BNordestgaard. We are honored to have you here in Miami!
1
4
26
Huge potential for ASCVD reduction: in women and men a 2 mmol/L (77 mg/dL) lower remnant cholesterol likely reduce 10-year risk of ASCVD by 13–17% & 15–20%, more in statin users than in non-users https://t.co/u3DEZsof3q Karen Hvid et al use modelling in CGPS & publish in EJPC
4
20
74
JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details https://t.co/IwwED8JYfE
3
45
144
EAS Congress late-breaking: In 273,770 US patients with ASCVD, higher Lp(a) levels drive continuously increasing risk of recurrent ASCVD events regardless of sex and race/ethnicity that may be partially mitigated by high impact LDL cholesterol lowering: https://t.co/BW23oEKEQS
6
23
74
The European Atherosclerosis Society Young Fellows have created a series of excellent podcasts - telling the more personal story of people whose research we sometimes read. Here is just one example, #11 and my own, one that I am very honored to have been invited to. Thanks!
In this episode of AtheroTalk, let's meet Prof. Børge Nordestgaard, the founder of the Copenhagen General Population Study and the current EAS President. Do you want to know more about his research trajectory, the mentors he met along the way, and the projects he's working on
1
4
40
The cardiovascular risk from high lipoprotein(a) explained by LDL-C, non–HDL-C, apoB, or hsCRP is minimal. Therefore, it is essential that all individuals at cardiovascular risk have lipoprotien(a) measured: https://t.co/E0DM6Dq7Lm Thomas PE in JACC open acces
5
27
91
Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease: Jan Boren+Chris Packard vs. Børge Nordestgaard. https://t.co/Zr4IZjZTAL Who wins? Here are the arguments - you decide - open acces
academic.oup.com
Triglycerides (TG) have long been recognized as a risk factor for atherosclerosis and cardiovascular disease. Nevertheless, controversial results have been
0
20
65
Elevated remnant cholesterol (and not LDL cholesterol) had a causal effect on risk of PAD. Time to take elevated remnant cholesterol seriously? Look for high triglycerides to find the patients. https://t.co/IZ0A6jp0Yi
4
21
83
An excellent reiew paper by Camilla Johannesen - on discordance analyses "Comparing LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B for Cardiovascular Risk Estimation" Published in Atherosclerosis. Wonderful simple explanations: https://t.co/fyoJ420dyc
3
17
68
Being diagnosed with familial hypercholesterolemia (FH) by the DLCN criteria depends on smoking, hypertension, BMI, and triglyceride and lipoprotein(a) concentrations. Being a man (or woman) with FH and having several of these factors is not nice: https://t.co/2na2o4AyxD
0
8
29